Findings from Nanyang Technological University Provide New Insights into Drug Delivery Systems (Millifluidic synthesis of amorphous drug-polysaccharide nanoparticle complex with tunable size intended for supersaturating drug delivery ...)
By a News Reporter-Staff News Editor at Drug Week Researchers detail new data in Drugs and Therapies - Drug Delivery Systems. According to news reporting originating in Singapore, Singapore, by NewsRx journalists, research stated, "The conventional bulk mixing method to prepare amorphous drug-polysaccharide nanoparticle complex (or drug nanoplex in short) has a major drawback in the lack of size control for the nanoplex produced, hence limiting its potential applications as a supersaturating drug delivery system for bioavailability enhancement of poorly soluble drugs. For this reason, we developed a continuous millifluidic synthesis platform of the drug nanoplex exhibiting high size tunability using curcumin (CUR) and chitosan (CHI) as the models for drug and polysaccharides, respectively."
Financial support for this research came from GlaxoSmithKline (see also Drugs and Therapies - Drug Delivery Systems).
The news reporters obtained a quote from the research from Nanyang Technological University, "The nanoplex size tunability was achieved by controlling the residence time of the CUR and CHI solutions in the millifluidic reactor, where their slow diffusive mixing at the liquid-liquid interface resulted in a well-regulated nanoplex growth as a function of the residence time. The effects of the preparation pH, molecular weight of CHI, millifluidic tube diameter, and flowrate on the nanoplex size tunability were investigated from which the optimal preparation condition was determined. At the optimal condition, the CUR nanoplex was roughly approximate to 115 nm in size with zeta potential of approximate to 15 mV and approximate to 172% (w/w) CUR payload. The millifluidic synthesis also maintained the high CUR utilization rate (approximate to 180%) exhibited by the bulk mixing method. Most importantly, the ability to produce significantly smaller nanoplex (sixfold smaller) via millifluidics led to the generation of higher (approximate to 8.5x of CUR saturation solubility) and prolonged (approximate to 8 h) supersaturation level."
According to the news reporters, the research concluded: "These results bode well for the bioavailability enhancement potential of the drug nanoplex."
For more information on this research see: Millifluidic synthesis of amorphous drug-polysaccharide nanoparticle complex with tunable size intended for supersaturating drug delivery applications. European Journal of Pharmaceutics and Biopharmaceutics, 2017;112():196-203. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.journals.elsevier.com/european-journal-of-pharmaceutics-and-biopharmaceutics/)
Our news correspondents report that additional information may be obtained by contacting K. Hadinoto, Nanyang Technological University, Sch Chem & Biomed Engn, Singapore 637459, Singapore. Additional authors for this research include M.H. Nguyen, Y.Z. Tan, J.W. Chew, S.A. Khan and K. Hadinoto.
Keywords for this news article include: Singapore, Singapore, Asia, Drug Delivery Systems, Emerging Technologies, Drugs and Therapies, Nanotechnology, Nanoplex, Nanyang Technological University.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC